By: Mila Federis
November 10, 2014
A recent decision of the Philippine Bureau of Legal Affairs (“BLA”) tackled the issue of distinctiveness in designations for pharmaceutical products. In Westmont Pharmaceutical, Inc. vs. Platinum Pharmaceuticals (PVT), Ltd. (IPC No. 14-2011-00153), 22 September 2014, the applicant attempted to register “OMEZOLE” as a trademark for “pharmaceutical preparations for the treatment of duodenal ulcer, gastric ulcer, gastro-esophageal reflex disease (gerd) and management of zollinger Ellison syndrome”. The application was opposed on grounds that OMEZOLE is confusingly similar to opponent’s registered trademark OMEPRON, which is also used in connection with “pharmaceutical preparations for the treatment of ulcer and gastritis”. Opponent further alleged that OMEZOLE resembles the generic name OMEPRAZOLE, a pharmaceutical drug used as proton pump inhibitor, and as such, registration is not permitted under Sections 123.1 (j) and 123.a(I) for being generic or descriptive.